Insider Cluster (4 insiders) ·Filed Jun 2, 2026

TWST

Twist Bioscience Corp
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago
Insider cluster: 4 insiders, $1.3M total
Actionable Insight • Neutral

Insider selling is routine and small relative to market cap. The CEO's option exercises and concurrent sales are standard liquidity/vesting activity. No bearish signal — monitor next earnings for fundamental trends.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
TWST ▲ +111.67% at T+60d
NEUTRAL call ✓ call won +111.67% · α vs SPY +109.17% · entry $72.33 → $153.10
Entry anchored
Jun 2, 03:59 PM ET
via exchange tick
T+1d
+2.21%
call +2.21% · α +1.81%
$73.93
settled 4mo ago
T+5d
-6.30%
call -6.30% · α -2.48%
$67.77
settled 4mo ago
T+20d
+37.20%
call +37.20% · α +38.20%
$99.24
settled 3mo ago
T+60d
+111.67%
call +111.67% · α +109.17%
$153.10
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Four insiders at Twist Bioscience sold a total of $1.31M in open-market sales over a 7-day window, including the CEO (via option exercise and sale) and the CFO. The cluster is dominated by a single large sale by Cho Dennis ($991K), and the total represents ~0.03% of market cap — well below the 0.1% threshold for materiality. The CEO's sales are tied to derivative exercises, a common liquidity pattern. This is a routine, low-significance cluster.

Key Financial Metrics

Direction
selling
Total Value
$1.3M
Insiders
4

Key Facts

  • 4 insiders sold shares totaling $1.31M in open-market transactions over 7 days
  • Total sales represent ~0.03% of Twist's $4.2B market cap — trivial
  • CEO Leproust exercised 83,000 options at $8.82 and sold a portion of the resulting shares
  • CFO Laponis sold $280K; Director Starovasnik sold $170K; CAO Werner sold $50K
  • No insider open-market purchases were reported in the cluster

Financial Impact

Total insider sales of $1.31M represent ~0.03% of market cap — immaterial

dilutioninsider ownership

Risk Factors

  • Insider selling could accelerate if stock continues to rise, but current levels are not alarming
  • No insider buying to offset — lack of bullish insider conviction is neutral, not bearish

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Biotech & Drug DiscoveryGenomics & Gene Editing

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TWST-1780430803897
27 reports for TWST
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+60▲ +52.11%May 4, 2026
Filters
Rows
Reports for TWST — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Insider Cluster
NEUTRAL ★ 2/10
$127.22 $166.99▲ +31.26%▲ +31.60%$188.67 (+48.30%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 4/10
$153.10 $128.71▼ −15.93%▼ −16.20%$188.67 (+23.23%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 4/10
$151.42 $132.06▼ −12.79%▼ −12.25%$188.67 (+24.60%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 4/10
$145.59 $141.38▼ −2.89%▼ −3.37%$188.67 (+29.59%)
Aug 20, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$136.23 $153.10▲ +12.38%▲ +11.27%$188.67 (+38.49%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$124.41 $140.80▲ +13.17%▲ +14.36%$188.67 (+51.65%)
Aug 14, 2026
7w ago
Insider Cluster
BEARISH ★ 6/10
$124.41 $140.80▼ −13.17%▼ −14.36%$188.67 (−51.65%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$125.29 $136.23▲ +8.73%▲ +10.70%$188.67 (+50.59%)
Aug 12, 2026
7w ago
144
NEUTRAL ★ 2/10
$125.29 $136.23▲ +8.73%▲ +10.70%$188.67 (+50.59%)
Aug 11, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$123.12 $116.10▼ −5.70%▼ −5.30%$188.67 (+53.24%)
Showing 10 of 27

US Market Status

Market Closed — Opens Mon (65h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 2, 2026